← Back to Search

Antidepressant

Antidepressants + Psychotherapy for Depression

Phase 3

Waitlist Available

Led By John C Perry, M.P.H., M.D.

Research Sponsored by Sir Mortimer B. Davis - Jewish General Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial will help researchers understand if a combination of medication and one of three types of commonly available psychotherapy can protect against the recurrence of depression.

Who is the study for?

This trial is for adults who are currently experiencing a major depressive episode and have had at least one before. They must score above 16 on a depression rating scale twice, one week apart. People with bipolar disorder, psychosis, high suicide risk needing hospitalization, serious substance abuse issues, organic mental disorders or those in early pregnancy or likely to move away during the study can't participate.Check my eligibility

What is being tested?

The study tests if taking antidepressants along with either Cognitive-behavioral therapy (CBT), Dynamic psychotherapy (DYN), or Supportive Clinical Management (SUP-CM) for 18 months helps prevent depression from coming back over three years. It also looks at psychological and economic benefits of these treatments.See study design

What are the potential side effects?

Antidepressant medications may cause side effects like nausea, weight gain, sleep disturbances, sexual dysfunction or increased anxiety initially. Psychotherapies generally don't have physical side effects but can sometimes lead to emotional discomfort as difficult topics are discussed.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Time to recovery of major depressive episode

Time to recurrence of major depression, once recovered

improvement in depressive defenses

Secondary outcome measures

cost-effectiveness measures

improvement on other specified psychological measures related to depression

proportion of time with depressive symptoms

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Sir Mortimer B. Davis - Jewish General HospitalLead Sponsor

55 Previous Clinical Trials

21,130 Total Patients Enrolled

John C Perry, M.P.H., M.D.Principal InvestigatorS.M.B.D. - Jewish General Hospital

Media Library

Antidepressive medications (ADM) (Antidepressant) Clinical Trial Eligibility Overview. Trial Name: NCT00220623 — Phase 3

Depression Clinical Trial 2023: Antidepressive medications (ADM) Highlights & Side Effects. Trial Name: NCT00220623 — Phase 3

Antidepressive medications (ADM) (Antidepressant) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00220623 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has this medication received FDA regulatory approval?

"This is a Phase 3 trial, which means that while there is still some testing to be done in regards to efficacy, the safety of the treatment has been supported by multiple rounds of data. Therefore, our team has given it a safety rating of 3."

Answered by AI

Are we still recruiting volunteers for this research project?

"No, this study is not currently looking for participants. However, this was a long-running trial, first posted on August 1st, 2004 and edited September 16th, 2005. There are many other trials (1344) that are presently open for recruitment."

Answered by AI

Do elderly patients qualify for this research?

"The age range for this study is 18-65, as this is the age bracket that the inclusion criteria allows."

Answered by AI

Might I be able to take part in this experiment?

"This experiment requires 30 individuals who suffer from major depressive disorder and are between 18-65 years old. The most crucial aspect is that participants must have had at least one prior major depressive episode (as per DSM-IV), a HRSD-17 score above 16 at screening and intake (one week apart)."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Efficacy of 18-Months of Antidepressive Medication Plus CBT or Dynamic or Supportive Psychotherapy for Recurrent Major Depression

2004. "Efficacy of 18-Months of Antidepressive Medication Plus CBT or Dynamic or Supportive Psychotherapy for Recurrent Major Depression". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00220623.

All > Major Depressive Disorder